Tazemetostat Setbacks Hit Epizyme

As drug fails in DLBCL, firm focuses on lifting partial clinical hold on other trials. A first filing in a rare sarcoma has also been pushed back.

Overcoming challenges and crisis . Mixed media
Epizyme faces clinical trial headwinds • Source: Shutterstock

Epigenetic cancer therapy specialist Epizyme Inc. has ended development of its lead product tazemetostat as a monotherapy or in combination with prednisolone for diffuse large B-cell lymphoma, or DLBCL. The company has also pushed back the expected timeline for submitting its US NDA for the drug's first indication of epithelioid sarcoma. And it disappointed investors in offering no clear timeline for the resolution of a partial clinical hold on trials of the drug during its second-quarter investor call.

The termination came after an evaluation of the level of clinical activity in the three DLBCL cohorts of a Phase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D